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Effect of angiotensin-converting enzyme inhibition on renal only lower blood pressure but also have beneficial side
filtration surface area in hypertensive rats. effects on the heart, systemic vasculature, and kidney
Background. Angiotensin-converting enzyme (ACE) inhib- [3–5]. In experimental models, control of hypertensionitor treatment leads to protective effects on the cellular struc-
with ACE inhibitors has renoprotective effects that leadture of the glomerulus and the kidney. The aim of this study was
to decreased interstitial fibrosis and decreased glomeru-to determine whether ACE inhibition increases renal filtration
surface area in the spontaneously hypertensive rat (SHR). losclerosis, thus protecting the kidney from progressive
Methods. SHR were treated with the ACE inhibitor perindo- glomerular injury [6–8]. It has also been shown in many
pril at a high dose (3 mg/kg/day) or a low dose (0.1 mg/kg/day) experimental studies that chronic treatment of the spon-during the period of hypertension development, from 7 to 14
taneously hypertensive rat (SHR) with an ACE inhibitorweeks of age. Some animals were treated concomitantly with the
leads to persistent reductions in blood pressure after with-bradykinin B2 receptor antagonist, S16118. Tail-cuff systolic blood
pressure and body weights were measured twice weekly. At termi- drawal of treatment [9–11]. Harrap, Wang and MacLel-
nation of treatment, glomerular number and volume, length, and lan suggest that the persistent effects of ACE inhibition
surface area of glomerular capillaries and renal filtration surface
on blood pressure are the result of changes in the kidney,area were estimated using unbiased stereological techniques.
since the blood pressure effects of ACE inhibitor treat-Results. There were significant dose-related reductions in
blood pressure with high- and low-dose perindopril treatment. ment follow the kidney in transplantation studies [12].
Neither low- nor high-dose perindopril treatment had any ef- In 1988, Brenner, Garcia and Anderson postulated that
fect on glomerular number or size or glomerular capillary length the major renal abnormality that initiates hypertension is
and surface area. Hence, there was no significant difference in
a decreased filtration surface area resulting from a reducedtotal renal filtration surface area between any of the experimen-
number of nephrons (glomeruli) and/or a decrease in fil-tal groups (8721  610 mm2 in untreated SHR and 7879  338
mm2 and 8767 437 mm2 in the low and high dose perindopril- tration surface area per glomerulus [13]. A reduction in
treated groups, respectively). Coadministration of the brady- filtration surface area is suggested to lead to sodium reten-
kinin antagonist did not affect any of the glomerular parameters. tion that ultimately leads to a rise in mean arterial bloodConclusions. ACE inhibition during the period of hyperten-
pressure. Systemic hypertension then leads to glomerularsion development does not lead to an enhanced glomerular
capillary hypertension and eventual glomerulosclerosis,capillary growth or increases in total renal filtration surface
area in this model. which in turn further decreases filtration surface area,
thus perpetuating a vicious cycle. Based on Brenner et al’s
hypothesis, it is possible that ACE inhibition treatment in
Hypertension plays a detrimental role in the progres- the kidney may increase renal filtration surface area,
sion of renal disease by accelerating glomerular damage either through preventing the pathological loss of glo-
and nephrosclerosis [1, 2]. Angiotensin-converting en- meruli and/or by stimulating glomerular capillary growth
zyme (ACE) inhibitors have developed as a preferred [13]. This could account for the persistent decreases in
pharmacological therapy for hypertension, as they not blood pressure following withdrawal of treatment.
Nephrogenesis occurs in early development. In the
human, nephrogenesis is complete at birth [14] and inKey words: ACE inhibition, blood pressure, kidney, glomerulus, perin-
dopril, capillary growth, progressive renal disease. the rat by approximately postnatal day 10 [15]. No new
nephrons are formed after this time. However, angiogen-Received for publication January 1, 2001
esis (the formation of new capillaries) is not precludedand in revised form May 15, 2001
Accepted for publication May 31, 2001 in the glomerulus after nephrogenesis [16, 17]. It is con-
ceivable that if angiogenesis could be induced in glomeruli 2001 by the International Society of Nephrology
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of hypertensive subjects, the glomerular filtration surface Measurement of systolic blood pressure
area would be increased, leading to a decreased systolic and body weight
blood pressure. In this regard, ACE inhibition has been Tail-cuff systolic blood pressure and body weights
suggested to have angiogenic properties in the myocar- were monitored twice weekly from 7 to 14 weeks of age.
dial vasculature of the SHR, with an increase in surface Systolic blood pressure was measured in pre-heated rats
area density and length density of capillaries described using a photoelectric tail-cuff pulse detection system
in the left ventricle following ACE inhibitor treatment (IITC Life Sciences, USA). The rats were preconditioned
[18]. In those studies, ACE inhibitor treatment both at to the procedure for two weeks prior to the starting date.
a high hypotensive dose and a low non-hypotensive dose
resulted in increased myocardial capillarization. The ob- Perfusion-fixation
served beneficial effects on capillary growth have been Rats were anesthetized with sodium pentobarbitone
suggested to be mediated by bradykinin [19]. This ques- (40 mg/kg intraperitoneally; Nembutal; Rhone Merieux,
tion arises: Can ACE inhibition increase filtration sur- Australia) and the abdominal aorta exposed via a mid-
face area in the kidney by enhancing glomerular capillary line incision. A catheter was inserted into the abdominal
growth and/or by preventing the pathological loss of aorta to administer heparin sodium (0.1 mL; Pharmacia
glomeruli? and Upjohn P/L, Australia) to prevent clotting, and pa-
To address this issue, our study treated SHRs from 7 paverine hydrochloride (0.1 mL; David Bull Labora-
to 14 weeks of age (the period of hypertension develop- tories, Australia) to dilate the vasculature. The vascula-
ment in this model) with the ACE inhibitor perindopril. ture was flushed with 0.9% sodium chloride solution
At termination of treatment, using unbiased stereologi- after severing the jugular artery and perfusion fixed with
cal techniques, we estimated glomerular number and size 2.5% glutaraldehyde (Chem-Supply P/L, Australia) in
and glomerular capillary length, surface area, and total 0.1 mol/L phosphate buffer (pH 7.4) at a pressure of 140
renal filtration surface area. mm Hg. The left kidney was then excised.
Tissue processing, sectioning, and stainingMETHODS
Perfusion-fixed left kidneys were cleaned of fat andAnimals
connective tissue and sliced at 1 mm in the horizontalSpontaneously hypertensive rats were obtained from
plane using a razor blade slicing device.the Animal Resource Centre (Perth, Western Australia)
Embedding in glycolmethacrylate. Every second kid-at an age of five weeks. All rats used were housed four
ney slice was sampled with the first chosen at random.or fewer to a box and maintained at an ambient tempera-
Kidney slices were dehydrated through graded alcoholture of 23 to 25C. Standard rat chow and water were
and infiltrated with glycolmethacrylate Technovit 7100supplied ad libitum. The animal experiments were ap-
Resin (Heraeus Kulzer, Germany) without hardenerproved by the Monash University, Department of Anat-
overnight, and then embedded in molds with Technovitomy Ethics Committee, and the treatment and care of
7100 with hardener and allowed to polymerize for 48the animals conformed with the Australian Code of Prac-
hours. Backing blocks using Technovit 3040 (Heraeustice for the Care and Use of Animals for Scientific Purposes.
Kulzer, Germany) were attached to the embedded blocks.
The thickness of each block (d1) was recorded with aDrug treatment
digital micrometer (Mitutoyo, Japan). The blocks wereThe SHR animals were treated by daily gavage with
exhaustively sectioned at 20 m, and the total numberthe ACE inhibitor perindopril from 7 to 14 weeks of age
of sections cut (N) was recorded. The block face distanceat a hypotensive dose of 3 mg/kg/day (high dose) or a
was remeasured (d2) using the digital micrometer andnon-hypotensive dose of 0.1 mg/kg/day (low dose). On
the average section thickness was calculated [t  (d1 the weekends, the perindopril was administered via the
d2)/N]. Every 10th and 11th section was sampled withdrinking water and the dose of drug was adjusted ac-
the first being chosen randomly (that is, between 1 andcording to amount of water consumed. SHRs gavaged
10) and mounted on glass slides. Sections were placed indaily with water were used for comparison. Half of the
a 60C oven and later stained with hematoxylin and eosin.animals from each group treated with the ACE inhibitor
Embedding in epon-araldite. Cubes of the cortex werewere concomitantly treated with the bradykinin antago-
sampled from the remaining kidney slices. Eight cubesnist S16118 (Institut de Recherches Internationales Ser-
from each kidney were randomly selected for furthervier, France) at a concentration of 10 ng/kg/day, which
processing. Cubes were washed in 0.1 mol/L phosphatewas administered subcutaneously via Alzet osmotic mini-
buffer (pH 7.3) containing 5% sucrose, dehydrated throughpumps (Alzet Co., USA). After four weeks, the minipumps
graded alcohol, washed in epoxy-propane (BDH Labo-were replaced with new pumps that lasted to the end of
the treatment period. ratory Supplies, UK) and infiltrated overnight in 50:50
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epoxy-propane:epon-araldite and the following night in fa  [Pkid  a(p)disector]/[Pf  a(p)microfiche]
pure epon-araldite. Tissue was then embedded in epon-
where Pkid was the number of grid points falling on kidneyaraldite and incubated at 60C for 48 hours.
tissue, Pf was the number of grid points overlying com-The epon-araldite blocks were sectioned at 1 m with
plete sections and a(p) was the area associated with each
five to ten sections cut from each block and stained with
grid point projected at a magnification of 178.5 on the
toluidine blue.
microscope and 24.3 on the microfiche.
Estimation of kidney volume
Estimation of glomerular volume
Kidney volume was determined in the glycolmethacry-
The same glycolmethacrylate sections were used to
late-embedded sections.
obtain unbiased estimates of mean glomerular volume.
The sampled sections (every 10th section) were pro-
An orthogonal grid placed in the unbiased counting
jected onto the screen of a Fuji Microfiche Minicopy
frame was used to estimate mean glomerular and mean
Reader (Model RF3A) at a magnification of 24.3. An
corpuscle volume. The number of grid points falling on
orthogonal grid was superimposed over the viewing screen
kidney tissue (Pkid), glomerular tufts (Pglom), and renaland the number of grid points overlying all kidney sec-
corpuscles (Pcorp) in the sampled area were counted.tions (Ps), as well as the number of points overlying com- Volume densities were then calculated by dividing the
plete sections (Pf) were counted. The final kidney volume total number of points overlying glomeruli or renal cor-
(Vkid) was estimated using the Cavalieri principle [20]: puscles by the number of points overlying kidney tissue.
Vkid  2  10  t  a(p)microfiche  Ps VVglom, kid  Pglom/Pkid
where 2 is the inverse of the slice sampling fraction, 10
VVcorp, kid  Pcorp/Pkidis the inverse of the section sampling fraction, t is the
mean section thickness, a(p) is the area associated with Mean glomerular tuft volume (Vglom) and mean renal
corpuscle volume (Vcorp) were estimated by dividing theeach grid point, and Ps is the total number of grid points
counted. volume densities in the kidney (VVglom, kid, VVcorp, kid) and
the numerical density of glomeruli in the kidney (NVglom, kid).
Estimation of glomerular number The numerical density of glomeruli in the kidney was
calculated by dividing NVglom, kid by Vkid.To estimate the total number of glomeruli in the kidney,
an unbiased stereological method known as the physical
Vglom  VVglom, kid/NVglom, kiddisector/fractionator combination was used [21, 22]. Only
complete 20 m glycolmethacrylate sections (Pf) were Vcorp  VVcorp, kid/NVglom, kid
used in the glomerular number estimation. Two Olympus
Stereological assessment of glomerularlight microscopes equipped for projection (BX50F4, Ja-
capillary growthpan) were used with the sampled (10th) section placed
on the stage of the first microscope and the correspond- Using an Olympus light microscope (BX50F4, Japan)
equipped for projection, the 1 m epon-araldite sectionsing look-up (11th) section placed on the stage of the
second microscope. The fields of vision were projected were projected at low magnification (4) onto a table
top. Two glomerular profiles were sampled from eachside-by-side with an unbiased counting frame applied to
the field of vision of the sampled section. The sample section using the method of Nyengaard [24]. These sam-
pled glomeruli were then projected onto a table top atmicroscope was equipped with a motorized stage with
an automated stepping action. The look-up microscope high magnification, using a 100 oil immersion lens.
An orthogonal grid was superimposed on the projectedhad a rotating stage attachment to facilitate section align-
ment. Glomeruli were counted if they were sampled by image, and the number of grid points falling on the renal
corpuscle (Pcorp), the number of capillary profiles withinan unbiased counting frame [23] in the sampled section,
but were not present in the look-up section and vice the renal corpuscle (Q), and the number of intersections
between the horizontal and vertical grid lines and theversa. The total number of glomeruli in a kidney was
estimated using the formula: capillary luminal surfaces (Icap) were counted.
Nglom,kid  2  10  (Ps/Pf)  (1/2fa)  Q Estimation of glomerular capillary length
The length of capillaries per unit volume of an averagewhere 2 is the inverse of the slice sampling fraction, 10
is the inverse of the section sampling fraction, Ps /Pf and renal corpuscle (LVcap, corp) was estimated using the for-
mula [21, 22]:1/2fa gives the fraction of the total section area used to
count glomeruli, and Q is the number of glomeruli
LVcap, corp  (2  Q)/[Pcorp  a(p)]counted.
The fraction of the section area (fa) was obtained using: where 2 is a constant, Q is the number of capillary profiles
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Fig. 2. Tail-cuff systolic blood pressure in SHR controls () and SHR
treated with either a low dose of perindopril (), a low dose of perindo-
pril plus S16118 (), a high dose of perindopril (), or a high dose ofFig. 1. Body weight in SHR controls () and SHR treated with either
perindopril plus S16118 () from 7 to 14 weeks of age. *P  0.05a low dose of perindopril (), a low dose of perindopril plus S16118
compared with SHR control; †P 0.05 SHR low dose plus B2 antagonist(), a high dose of perindopril (), or a high dose of perindopril plus
compared with SHR low dose; ‡P  0.05 SHR high dose plus B2S16118 () from 7 to 14 weeks of age. *P  0.05 compared with SHR
antagonist compared with SHR high dose.control; †P  0.05 SHR low dose plus B2 antagonist compared with
SHR low dose.
capillaries in an average renal corpuscle by the total
within the renal corpuscle profile, Pcorp is the number of number of glomeruli in the kidney.
grid points falling on the renal corpuscle, and a(p) is the
FSA  Scap, corp  Nglom, kidarea associated with each grid point.
From this, the total length of capillaries in an average Statistical analysis
corpuscle was estimated by multiplying the length den-
Data were analyzed using GraphPad Prism versionsity of capillaries in the renal corpuscle by mean renal
2.00 for Windows (GraphPad Software, USA). To com-corpuscle volume:
pare stereological data at the termination of treatment
Lcap, corp  LVcap, corp  Vcorp a one-way analysis of variance was performed. A two-
way analysis of variance was used to determine the differ-Estimation of capillary surface area
ences in body weight and blood pressure between groups
The surface density of capillaries (SVcap, corp) was esti- over time. A P of 0.05 or less was considered statistically
mated using the formula [21, 22]: significant. Results are expressed as means  SEM.
SVcap, corp  (2  Icap)/(Pcorp  k  d)
RESULTSwhere 2 is a constant, Icap is the total number of intersec-
tions between the grid and the capillary wall, Pcorp is the Body weight
number of grid points falling on the renal corpuscle, k Low-dose and high-dose perindopril treatments had
is 2 for an orthogonal grid, and d is the length of each no effect (P  0.05) on body weight in the SHR, with
grid line adjusted for magnification. the gain in body weight also not affected (Fig. 1). Con-
The total surface area of capillaries in an average comitant treatment with the bradykinin antagonist
renal corpuscle was then calculated by multiplying the S16118 had no effect (P  0.05) on growth in the high-
surface density of capillaries in the corpuscle (SVcap, corp) dose perindopril-treated group, but did significantly in-
by mean renal corpuscle volume: crease (P  0.0001) the change in weight over time in
the low-dose perindopril treatment group.Scap, corp  SVcap, corp  Vcorp
Systolic blood pressureEstimation of total renal filtration surface area
During the experimental period, the blood pressureThe total filtration surface area (FSA) of the kidney
was estimated by multiplying the total surface area of of the control SHR increased initially and then remained
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Table 1. Kidney weight and stereological estimates of kidney volume, glomerular number, glomerular volume and renal corpuscle volume
in the spontaneously hypertensive rat (SHR) and in SHR treated from 7 to 14 weeks of age with either a low dose of perindopril,
a low dose of perindopril plus S16118, a high dose of perindopril or a high dose of perindopril plus S16118
Glomerular Renal corpuscle
volume volume
SHR Kidney Kidney volume Glomerular
Treatment N weight g 103 mm3 number N 103 mm3
SHR control 8 1.480.06 1.240.07 252341314 1.590.09 2.080.09
SHR low dose 7 1.460.04 1.320.09 268561408 1.60.15 1.930.17
SHR low dose 	 B2 antagonist 7 1.650.07 1.120.09 251961369 1.460.19 1.970.18
SHR high dose 8 1.550.06 1.310.08 272871479 1.450.08 1.960.09
SHR high dose 	 B2 antagonist 6 1.500.03 1.160.07 269051088 1.380.14 1.880.12
Values are mean  SEM.
Table 2. Stereological estimates of capillary length per average renal corpuscle, capillary surface area per average renal corpuscle, and total
kidney filtration surface area in the spontaneously hypertensive rat (SHR) and in SHR treated from 7 to 14 weeks of age with either
a low dose of perindopril, a low dose of perindopril plus S16118, a high dose of perindopril or a high dose of perindopril plus S16118
Glomerular Glomerular capillary Total filtration
SHR capillary length surface area surface area
Treatment N mm 101 mm2 10 3 mm2
SHR control 8 13.70.8 3.540.17 8.720.61
SHR low dose 7 11.71.0 3.00.22 7.880.34
SHR low dose 	 B2 antagonist 7 13.21.2 3.400.36 8.891.35
SHR high dose 8 10.70.8 3.250.19 8.770.44
SHR high dose 	 B2 antagonist 6 11.50.6 3.030.16 8.330.60
Values are means  SEM.
approximately 210 mm Hg (Fig. 2). Blood pressure re- Glomerular capillary length and surface area
mained at a normotensive level in SHRs treated with a At 14 weeks of age, the length and surface area of
high dose of perindopril. Administration of the bradykinin capillaries in average glomeruli in the five groups were
antagonist significantly (P  0.001) increased the level similar (P  0.44 and P  0.13, respectively; Table 2).
of blood pressure in SHRs treated with the high dose of
perindopril. SHRs treated with a low dose of perindopril Total renal filtration surface area
remained hypertensive, although blood pressure in these At 14 weeks of age, there were no differences (P 
animals was significantly (P  0.001) lower than in con- 0.85) in total renal filtration surface area between the
trol SHRs. In contrast to that observed in SHRs treated five groups of rats (Table 2).
with a high dose of perindopril, concomitant treatment
with the bradykinin antagonist S16118 significantly (P
DISCUSSION0.001) lowered blood pressure even further in the low
dose treatment group. In this study, ACE inhibitor treatment in SHRs during
the period of hypertension development, at either a low
Kidney weight and volume dose or high dose, did not affect glomerular number or
Treatment of SHRs with either a high or low dose of size or total renal filtration surface area. There was no
perindopril had no significant effect on kidney weight evidence of increased capillary growth in the glomeruli
(P  0.08) or volume (P  0.32). of ACE inhibitor-treated animals, with the length and
Similarly, concomitant treatment with the bradykinin surface area of glomerular capillaries similar in all groups.
antagonist S16118 had no effect on kidney weight or Following ACE inhibition treatment, there was no
volume in either the high dose or low dose treated groups significant increase in renal filtration surface area through
(Table 1). enhancement of glomerular capillary growth. Unlike pre-
vious studies reported in the heart, there was no evidence
Glomerular number and volume to suggest that ACE inhibition could enhance glomerular
capillarization, with no change in glomerular capillaryThe total glomerular number in the five groups of rats
was similar (P  0.69). There were also no significant length and surface area between controls and those
treated with either a low dose or high dose of perindopril.differences in glomerular (P  0.72) or renal corpuscle
(P  0.87) volume between the five groups (Table 1). Hence, the persistent effects of ACE inhibitors, observed
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